helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2021-14-4-149-153helmholtzeyeinstitute-800Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWSСовременное представление о новой группе васкулитов сетчаткиModern concept of a new group of retinal vasculitishttps://orcid.org/0000-0003-0057-3338ЛоскутовИ. А.LoskutovI. A.

Игорь Анатольевич Лоскутов — д-р мед. наук, руководитель офтальмологического отделения

ул. Щепкина, д. 61/2, Москва, 129110

Igor A. Loskutov — Dr. of Med. Sci., head of ophthalmological department

61/2, Schepkina St., Moscow, 129110

https://orcid.org/0000-0002-5952-2183КоврижкинаА. А.KovrizhkinaA. A.

Алина Алексеевна Коврижкина — научный сотрудник офтальмологического отделения

ул. Щепкина, д. 61/2, Москва, 129110

Alina A. Kovrizhkina — researcher, ophthalmological department

61/2, Schepkina St., Moscow, 129110

АндрюхинаО. М.AndryuhinaO. M.

Ольга Михайловна Андрюхина — канд. мед. наук, старший научныйсотрудник офтальмологического отделения

ул. Щепкина, д. 61/2, Москва, 129110

Olga M. Andryuhina — Cand. of Med. Sci., senior researcher, ophthalmological department

61/2, Schepkina St., Moscow, 129110

a-olya86@mail.ruГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»РоссияMoscow Regional Research and Clinical Institute (MONIKI)Russian Federation202104012022144149153Copyright © Лоскутов И.А., Коврижкина А.А., Андрюхина О.М., 20222022Лоскутов И.А., Коврижкина А.А., Андрюхина О.М.Loskutov I.A., Kovrizhkina A.A., Andryuhina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/800

Ретинальные васкулиты — это редкое состояние, которое встречается при системных тяжелых заболеваниях и как нежелательное явление после введения медикаментозных препаратов в полость глаза. С появлением новых анти-VEGF препаратов в зарубежной литературе появился ряд публикаций о возникновении ретинальных окклюзирующих васкулитов, которые приводили к снижению остроты зрения. В обзоре представлен возможный патогенез развития данного состояния, подходы к его диагностике и алгоритм ведения пациентов с окклюзирующими васкулитами.

Retinal vasculitis is a rare condition that occurs both in systemic severe diseases and as an adverse event of intraocular drug injections. With the emergence of new anti-VEGF drugs, a number of international authors report on the occurrence of retinal occlusive vasculitis, which led to a decrease in visual acuity. The review presents possible pathogeneses of this condition, approaches to its diagnosis and an algorithm for managing the patients with occlusive vasculitis.

васкулитыокклюзирующий васкулитбролуцизумабанти-VEGFvasculitisocclusive vasculitisbrolucizumabanti-VEGFReferencesKu J.H., Ali A., Suhler E.B., Choi D., Rosenbaum J.T. Characteristics and visual outcome of patients with retinal vasculitis. Arch. Ophthalmol. 2012; 130 (10): 1261–6. doi: 10.1001/archophthalmol.2012.1596Ku J.H., Ali A., Suhler E.B., Choi D., Rosenbaum J.T. Characteristics and visual outcome of patients with retinal vasculitis. Arch. Ophthalmol. 2012; 130 (10): 1261–6. doi: 10.1001/archophthalmol.2012.1596Herbort C.P., Cimino L., Abu E.L., Asrar A.M. Ocular vasculitis: a multidisciplinary approach. Curr. Opin. Rheumatol. 2005; 17 (1): 25–33. doi: 10.1097/01.bor.0000149083.16639.7eHerbort C.P., Cimino L., Abu E.L., Asrar A.M. Ocular vasculitis: a multidisciplinary approach. Curr. Opin. Rheumatol. 2005; 17 (1): 25–33. doi: 10.1097/01.bor.0000149083.16639.7eBrydak-Godowska J., Dróbecka-Brydak E. [Retinal vasculitis — causes, diagnosis, treatment]. Klin. Oczna. 2007; 109 (1–3): 71–3.Brydak-Godowska J., Dróbecka-Brydak E. [Retinal vasculitis — causes, diagnosis, treatment]. Klin. Oczna. 2007; 109 (1–3): 71–3.Donaldson L., Margolin E. Vision loss in giant cell arteritis. Pract. Neurol. 2021 Jul 8. Available at: http://dx.doi.org/10.1136/practneurol-2021-002972.Donaldson L., Margolin E. Vision loss in giant cell arteritis. Pract. Neurol. 2021 Jul 8. Available at: http://dx.doi.org/10.1136/practneurol-2021-002972.Yang Shizhao, Huang Zhaohao, Hu Yunwei, et al. The efficacy of adalimumab as an initial treatment in patients with Behçet's retinal vasculitis. Frontiers in pharmacology. 2021; 12: 609148. doi:10.3389/fphar.2021.609148Yang Shizhao, Huang Zhaohao, Hu Yunwei, et al. The efficacy of adalimumab as an initial treatment in patients with Behçet's retinal vasculitis. Frontiers in pharmacology. 2021; 12: 609148. doi:10.3389/fphar.2021.609148Russo R., Katsicas M. Takayasu Arteritis. Frontiers in pediatrics. 2018; 6: 265. doi: 10.3389/fped.2018.00265Russo R., Katsicas M. Takayasu Arteritis. Frontiers in pediatrics. 2018; 6: 265. doi: 10.3389/fped.2018.00265Chun Y.S., Park S.J., Park I.K., Chung H., Lee J. The clinical and ocular manifestations of Takayasu arteritis. Retina. 2001; 21 (2): 132–40. doi: 10.1097/00006982-200104000-00006Chun Y.S., Park S.J., Park I.K., Chung H., Lee J. The clinical and ocular manifestations of Takayasu arteritis. Retina. 2001; 21 (2): 132–40. doi: 10.1097/00006982-200104000-00006Устинова Е.И. К классификации эндогенных увеитов. Офтальмологические ведомости. 2016; 9 (2): 74–80.Ustinova E.I. Classification of endogenous uveitis. Oftal'mologicheskie vedomosti. 2016; 9 (2): 74–80 (in Russian).Баранов А.А. Системные васкулиты: современные стандарты диагностики и лечения. Русский медицинский журнал. 2005; 24: 1577.Baranov A.A. Systemic vasculitis: modern standards for diagnosis and treatment. Russkij meditsinskij zhurnal. 2005; 24: 1577 (in Russian).Hughes E.H, Dick A.D. The pathology and pathogenesis of retinal vasculitis. Neuropathol. Appl. Neurobiol. 2003; 29 (4): 325–40. doi: 10.1046/j.1365-2990.2003.00499.xHughes E.H, Dick A.D. The pathology and pathogenesis of retinal vasculitis. Neuropathol. Appl. Neurobiol. 2003; 29 (4): 325–40. doi: 10.1046/j.1365-2990.2003.00499.xJabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am. J. Ophthalmol. 2005; 140 (3): 509–16. doi: 10.1016/j.ajo.2005.03.057Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am. J. Ophthalmol. 2005; 140 (3): 509–16. doi: 10.1016/j.ajo.2005.03.057Prete M., Indiveri F., Perosa F. Vasculitides: Proposal for an integrated nomenclature. Autoimmun Rev. 2016; 15 (2): 167–73. doi: 10.1016/j.autrev.2015.10.008Prete M., Indiveri F., Perosa F. Vasculitides: Proposal for an integrated nomenclature. Autoimmun Rev. 2016; 15 (2): 167–73. doi: 10.1016/j.autrev.2015.10.008Datoo O'Keefe G.A., Rao N. Retinal vasculitis: A framework and proposal for a classification system. Surv Ophthalmol. 2021; 66 (1): 54–67. doi: 10.1016/j.survophthal.2020.05.004Datoo O'Keefe G.A., Rao N. Retinal vasculitis: A framework and proposal for a classification system. Surv Ophthalmol. 2021; 66 (1): 54–67. doi: 10.1016/j.survophthal.2020.05.004Witkin A.J., Chang D.F., Jumper J.M., et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes. Ophthalmology. 2017; 124 (5): 583–95. doi: 10.1016/j.ophtha.2016.11.042Witkin A.J., Chang D.F., Jumper J.M., et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes. Ophthalmology. 2017; 124 (5): 583–95. doi: 10.1016/j.ophtha.2016.11.042Muid J., Awan M.A. Haemorrhagic occlusive retinal vasculitis caused by intravitreal vancomycin. J. Pak. Med. Assoc. 2020; 70 (9): 1648–50. doi: 10.5455/JPMA.46528Muid J., Awan M.A. Haemorrhagic occlusive retinal vasculitis caused by intravitreal vancomycin. J. Pak. Med. Assoc. 2020; 70 (9): 1648–50. doi: 10.5455/JPMA.46528El Gendy H.A. Vancomycin-associated retinal hemorrhages in pediatric age group: A case report. Am. J. Ophthalmol. Case Rep. 2020; 20: 100880. doi: 10.1016/j.ajoc.2020.100880El Gendy H.A. Vancomycin-associated retinal hemorrhages in pediatric age group: A case report. Am. J. Ophthalmol. Case Rep. 2020; 20: 100880. doi: 10.1016/j.ajoc.2020.100880Witkin A.J., Shah A.R., Engstrom R.E., et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015; 122 (7): 1438–51. doi: 10.1016/j.ophtha.2015.03.016Witkin A.J., Shah A.R., Engstrom R.E., et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015; 122 (7): 1438–51. doi: 10.1016/j.ophtha.2015.03.016Jiao B., You E., Chemali K., et al. Ocular inflammatory and retinal vascular occlusive adverse events of intravitreal anti-VEGF injections: A systematic review and network meta-analysis. Invest. Ophthalmol. Vis. Sci. 2021; 62: 453. https://iovs.arvojournals.org/article.aspx?articleid=2772806Jiao B., You E., Chemali K., et al. Ocular inflammatory and retinal vascular occlusive adverse events of intravitreal anti-VEGF injections: A systematic review and network meta-analysis. Invest. Ophthalmol. Vis. Sci. 2021; 62: 453. https://iovs.arvojournals.org/article.aspx?articleid=2772806Von Hanno T., Kinge B., Fossen K. Retinal artery occlusion following intravitreal anti VEGF therapy. Acta ophthalmologica. 2010; 88 (2): 263–6. doi: 10.1111/j.1755-3768.2008.01406.xVon Hanno T., Kinge B., Fossen K. Retinal artery occlusion following intravitreal anti VEGF therapy. Acta ophthalmologica. 2010; 88 (2): 263–6. doi: 10.1111/j.1755-3768.2008.01406.xWitkin A.J., Hahn P., Murray T.G., et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J. Vitreoretin Dis. 2020; 4 (4): 269–79. doi:10.1177/2474126420930863Witkin A.J., Hahn P., Murray T.G., et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J. Vitreoretin Dis. 2020; 4 (4): 269–79. doi:10.1177/2474126420930863Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am. J. Ophthalmol. Case Rep. 2020; 18: 100687. doi: 10.1016/j.ajoc.2020.100687Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am. J. Ophthalmol. Case Rep. 2020; 18: 100687. doi: 10.1016/j.ajoc.2020.100687Antaki F., Vadboncoeur J. Retinal vasculitis after intravitreal injection of brolucizumab. Can. J. Ophthalmol. 2021 May 7:S0008-4182(21)00133-2. doi: 10.1016/j.jcjo.2021.04.004Antaki F., Vadboncoeur J. Retinal vasculitis after intravitreal injection of brolucizumab. Can. J. Ophthalmol. 2021 May 7:S0008-4182(21)00133-2. doi: 10.1016/j.jcjo.2021.04.004Leclaire M.D., Lauermann J., Alten F., Eter N. Intraokuläre Entzündung mit okklusiver retinaler Vaskulitis nach intravitrealer Brolucizumab-Injektion [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. Ophthalmologe. 2021 Feb 24. German. doi: 10.1007/s00347-021-01341-4Leclaire M.D., Lauermann J., Alten F., Eter N. Intraokuläre Entzündung mit okklusiver retinaler Vaskulitis nach intravitrealer Brolucizumab-Injektion [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. Ophthalmologe. 2021 Feb 24. German. doi: 10.1007/s00347-021-01341-4Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi: 10.1007/s00347-021-01321-8Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi: 10.1007/s00347-021-01321-8Hikichi T. Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn. J. Ophthalmol. 2021; 65 (2): 208–14. doi: 10.1007/s10384-021-00819-7Hikichi T. Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn. J. Ophthalmol. 2021; 65 (2): 208–14. doi: 10.1007/s10384-021-00819-7Iyer P.G., Peden M.C., Suñer I.J., et al. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am. J. Ophthalmol. Case Rep. 2020; 20: 100989. doi:10.1016/j.ajoc.2020.100989Iyer P.G., Peden M.C., Suñer I.J., et al. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am. J. Ophthalmol. Case Rep. 2020; 20: 100989. doi:10.1016/j.ajoc.2020.100989Sharma A., Kumar N., Parachuri N., et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam's Razor? Ocul. Immunol. Inflamm. 2021; May 20: 1–3. doi: 10.1080/09273948.2021.1897628Sharma A., Kumar N., Parachuri N., et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam's Razor? Ocul. Immunol. Inflamm. 2021; May 20: 1–3. doi: 10.1080/09273948.2021.1897628Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. American Journal of Ophthalmology Case Reports. 2020; 18: 100687. doi:10.1016/j.ajoc.2020.100687Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. American Journal of Ophthalmology Case Reports. 2020; 18: 100687. doi:10.1016/j.ajoc.2020.100687Monés J., Srivastava S.K., Jaffe G.J., et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021; 128 (7): 1050–9. doi: 10.1016/j.ophtha.2020.11.011Monés J., Srivastava S.K., Jaffe G.J., et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021; 128 (7): 1050–9. doi: 10.1016/j.ophtha.2020.11.011Baumal C.R., Spaide R.F., Vajzovic L., et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020; 127 (10): 1345–59. doi: 10.1016/j.ophtha.2020.04.017Baumal C.R., Spaide R.F., Vajzovic L., et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020; 127 (10): 1345–59. doi: 10.1016/j.ophtha.2020.04.017Зорников Д.Л., Литусов Н.В., Новоселов А.В. Иммунопатология. Екатеринбург: Изд-во УГМУ; 2017.Zornikov D.L., Litusov N.V., Novoselov A.V. Immunopathology. Ekaterinburg: UGMU; 2017 (in Russian).Mauldin E.A., Peters-Kennedy J. Integumentary System. Jubb, Kennedy & Palmer's Pathology of Domestic Animals: Volume 1. 2016; 509–736.e1. doi:10.1016/B978-0-7020-5317-7.00006-0Mauldin E.A., Peters-Kennedy J. Integumentary System. Jubb, Kennedy & Palmer's Pathology of Domestic Animals: Volume 1. 2016; 509–736.e1. doi:10.1016/B978-0-7020-5317-7.00006-0Hsu Y.O., Lu K.L., Fu Y., et al. The roles of immunoregulatory networks in severe drug hypersensitivity. Frontiers in immunology. 2021; 12: 597761. https://doi.org/10.3389/fimmu.2021.597761Hsu Y.O., Lu K.L., Fu Y., et al. The roles of immunoregulatory networks in severe drug hypersensitivity. Frontiers in immunology. 2021; 12: 597761. https://doi.org/10.3389/fimmu.2021.597761Haug S.J., Hien D.L., Uludag G., et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. American journal of ophthalmology case reports. 2020; 18: 100680. https://doi.org/10.1016/j.ajoc.2020.100680Haug S.J., Hien D.L., Uludag G., et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. American journal of ophthalmology case reports. 2020; 18: 100680. https://doi.org/10.1016/j.ajoc.2020.100680Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi:10.1007/s00347-021-01321-8Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi:10.1007/s00347-021-01321-8Assessment report Beovu International non-proprietary name: brolucizumab Procedure No. EMEA/H/C/004913/0000. 12 December 2019 EMA/23630/2020 Committee for Medicinal Products for Human Use (CHMP) Available at: https://www.ema.europa.eu/en/documents/assessment-report/beovu-epar-public-assessment-report_en.pdfAssessment report Beovu International non-proprietary name: brolucizumab Procedure No. EMEA/H/C/004913/0000. 12 December 2019 EMA/23630/2020 Committee for Medicinal Products for Human Use (CHMP) Available at: https://www.ema.europa.eu/en/documents/assessment-report/beovu-epar-public-assessment-report_en.pdfNovartis. Safety of Beovu®(brolucizumab). Available at: https://www.brolucizumab.infoNovartis. Safety of Beovu®(brolucizumab). Available at: https://www.brolucizumab.infoKunimoto D., Yoon Y.H., Wykoff C.C., et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020; 127: 10: 1331-44. doi: 10.1016/j.ophtha.2020.03.035Kunimoto D., Yoon Y.H., Wykoff C.C., et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020; 127: 10: 1331-44. doi: 10.1016/j.ophtha.2020.03.035Hussain R.M., Weng C.Y., Wykoff C.C., Gandhi R.A., Hariprasad S.M. Abicipar pegol for neovascular age-related macular degeneration. Expert opinion on biological therapy. 2020; 20 (9): 999–1008. doi: 10.1080/14712598.2020.1782379Hussain R.M., Weng C.Y., Wykoff C.C., Gandhi R.A., Hariprasad S.M. Abicipar pegol for neovascular age-related macular degeneration. Expert opinion on biological therapy. 2020; 20 (9): 999–1008. doi: 10.1080/14712598.2020.1782379Информационное письмо от 18.08.2021 № 02И-1035/21. О новых данных по безопасности лекарственного препарата Визкью® (МННбролуцизумаб) Available at: https://roszdravnadzor.gov.ru/documents/74091Information letter dated 08/18/2021 No. 02I-1035/21. About new safety data of the drug Beovue® ( brolucizumab) (In Russian) Available at: https://roszdravnadzor.gov.ru/documents/74091Witkin A. J., Hahn P., Murray T.G., et al. Research and Safety in Therapeutics Committee, American Society of Retina Specialists. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. Journal of VitreoRetinal Diseases, 2021; 5 (4): 326–32. doi: 10.1177/2474126420975303Witkin A. J., Hahn P., Murray T.G., et al. Research and Safety in Therapeutics Committee, American Society of Retina Specialists. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. Journal of VitreoRetinal Diseases, 2021; 5 (4): 326–32. doi: 10.1177/2474126420975303Baumal C.R., Bodaghi B., Singe M., et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmology Retina. 2021; 5 (6): 519–27. doi:10.1016/j.oret.2020.09.020Baumal C.R., Bodaghi B., Singe M., et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmology Retina. 2021; 5 (6): 519–27. doi:10.1016/j.oret.2020.09.020Sharma A., Kumar N., Parachuri N., et al. Brolucizumab — foreseeable workflow in the current scenario. Eye. 2021; 35(6): 1548-50. doi: 10.1038/s41433-020-01324-wSharma A., Kumar N., Parachuri N., et al. Brolucizumab — foreseeable workflow in the current scenario. Eye. 2021; 35(6): 1548-50. doi: 10.1038/s41433-020-01324-wNesrine A., Sourour Z., Molka K., et al. Diagnosing retinal vasculitis and its implications for treatment. Expert Review of Ophthalmology. 2019; 14 (3): 151–67. https://doi.org/10.1080/17469899.2019.1613153Nesrine A., Sourour Z., Molka K., et al. Diagnosing retinal vasculitis and its implications for treatment. Expert Review of Ophthalmology. 2019; 14 (3): 151–67. https://doi.org/10.1080/17469899.2019.1613153Wang P., Chin E.K., Almeida D.R. Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions. Am. J. Ophthalmol. Case Rep. 2021; 22: 101086. doi:10.1016/j.ajoc.2021.101086Wang P., Chin E.K., Almeida D.R. Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions. Am. J. Ophthalmol. Case Rep. 2021; 22: 101086. doi:10.1016/j.ajoc.2021.101086

The authors declare that there are no conflicts of interest present.